| AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms (NCT05198960) | University Hospital, Brest | 2022-07-13 |
| Ruxolitinib in Thrombocythemia and Polycythemia Vera (NCT04644211) | Massachusetts General Hospital | 2022-03-21 |
| An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms (NCT05123365) | University of California, Irvine | 2022-01-03 |
| Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI) (NCT04942080) | University Hospital, Angers | 2021-10-28 |
| Two Step Haplo With Radiation Conditioning (NCT05031897) | Thomas Jefferson University | 2021-10-25 |
| IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV) (NCT04262141) | Terrence J Bradley, MD | 2020-10-02 |
| Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003) (NCT04254978) | Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) | 2020-09-08 |
| Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms. (NCT03869476) | University Hospital, Angers | 2019-07-30 |
| Dual Vaccine Trial in Myeloproliferative Neoplasms (NCT04051307) | Inge Marie Svane | 2019-07-10 |
| CPAP in Treating Obstructive Sleep Apnea in Patients With Polycythemia Vera or Essential Thrombocythemia (NCT03972943) | University of Utah | 2019-05-15 |
| Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT03862157) | M.D. Anderson Cancer Center | 2019-02-27 |
| Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms (NCT03878199) | Ohio State University Comprehensive Cancer Center | 2019-02-20 |
| The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase (NCT03907436) | University of California, Irvine | 2018-10-01 |
| Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia (NCT03289910) | National Cancer Institute (NCI) | 2018-09-24 |
| Secondary Cancers in Myeloproliferative Neoplasms (MPN-K Study) (NCT03745378) | FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS | 2018-05-15 |
| 18F-FLT (PET/CT) in Pediatrics With Myeloproliferative Neoplasms (NCT03121599) | Hamad Medical Corporation | 2017-06-11 |
| Anagre Cap. in Patients With High-Risk Essential Thrombocythemia (NCT03232177) | Yuhan Corporation | 2017-06-05 |
| Endoplasmic Reticulum Stress and Resistance to Treatments in Ph-negative Myeloproliferative Neoplasms (NCT02823184) | University Hospital, Bordeaux | 2017-04-27 |
| Ultrasound Examination for Spleen Volume Evaluation in Myeloproliferative Neoplasms (NCT06371573) | Federico II University | 2017-04-20 |
| The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line (NCT02962388) | French Innovative Leukemia Organisation | 2017-01-03 |
| Cell Cycle Regulatory Gene Study in Patients With Myeloproliferative Disorders (NCT02663648) | Shandong University | 2016-06-01 |
| Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia (NCT02611973) | Assistance Publique - Hôpitaux de Paris | 2016-03-10 |
| Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies (NCT02556931) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2015-12-01 |
| Myeloproliferative Neoplastic Diseases Observatory From Brest (NCT02897297) | University Hospital, Brest | 2015-09-01 |
| Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation (NCT02311569) | Swiss Cancer Institute | 2015-04-01 |
| Myeloproliferative Neoplasms (MPNs) Patient Registry (NCT02760238) | University Health Network, Toronto | 2015-04-01 |
| Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia (NCT02407080) | John Mascarenhas | 2015-04-01 |
| Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies (NCT02129101) | Mayo Clinic | 2014-05-01 |
| Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia (NCT02124746) | Sierra Oncology LLC - a GSK company | 2014-04-30 |
| Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia (NCT01998828) | Sierra Oncology LLC - a GSK company | 2014-02-19 |
| Anagrelide Retard in Essential Thrombocythemia (NCT02076815) | AOP Orphan Pharmaceuticals AG | 2014-02-01 |
| A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF (NCT01787552) | Novartis Pharmaceuticals | 2013-05-08 |
| Myeloproliferative Neoplasms: an In-depth Case-control Study (NCT01831635) | Queen's University, Belfast | 2013-04-01 |
| Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant (NCT01588015) | City of Hope Medical Center | 2012-10-29 |
| Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients (NCT01970930) | Icahn School of Medicine at Mount Sinai | 2012-08-01 |
| Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms (NCT01520220) | Eli Lilly and Company | 2012-06-11 |
| A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms (NCT01387763) | Thomas Stauffer Larsen | 2012-01-01 |
| A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies (NCT01384513) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2011-08-04 |
| Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant (NCT01199562) | City of Hope Medical Center | 2010-12-01 |
| Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera (NCT01243073) | Geron Corporation | 2010-12-01 |
| French Observational Xagrid (FOX) Study In Adult Patients With Essential Thrombocythemia (NCT01192347) | Shire | 2010-09-13 |
| Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer (NCT01053494) | Wake Forest University Health Sciences | 2010-04-01 |
| Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy (NCT00890747) | National Cancer Institute (NCI) | 2009-08-01 |
| A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia (NCT00866762) | Copenhagen University Hospital at Herlev | 2009-02-01 |
| A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis (NCT00745550) | S*BIO | 2008-08-01 |
| Study of LY573636-sodium in Essential Thrombocythemia and Acute Myeloid Leukemia (NCT00718159) | Eli Lilly and Company | 2008-08-01 |
| CEP-701 (Lestaurtinib) in Myelofibrosis (NCT00668421) | Ronald Hoffman | 2008-04-01 |
| Familial Myeloproliferative Disorders (NCT00666289) | Icahn School of Medicine at Mount Sinai | 2008-03-01 |
| Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders (NCT00588991) | National Cancer Institute (NCI) | 2008-02-04 |
| Research Tissue Bank (NCT00666549) | Icahn School of Medicine at Mount Sinai | 2007-09-01 |
| Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer (NCT00489203) | Fred Hutchinson Cancer Center | 2007-04-01 |
| Correlative Biomarker Study in Patients With Myeloproliferative Disorders (NCT00665067) | Icahn School of Medicine at Mount Sinai | 2007-04-01 |
| Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome (NCT00445744) | Fred Hutchinson Cancer Center | 2006-12-01 |
| 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia (NCT00381550) | National Cancer Institute (NCI) | 2006-08-01 |
| Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes (NCT00715247) | University of Utah | 2006-07-01 |
| Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders (NCT00357305) | National Cancer Institute (NCI) | 2006-05-01 |
| Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders (NCT00397813) | Fred Hutchinson Cancer Center | 2006-01-01 |
| Lenalidomide and Prednisone in Treating Patients With Myelofibrosis (NCT00227591) | National Cancer Institute (NCI) | 2005-12-01 |
| Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer (NCT00089011) | Fred Hutchinson Cancer Center | 2004-04-01 |
| Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation (NCT00052520) | Fred Hutchinson Cancer Center | 2002-09-01 |
| Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia (NCT00047190) | National Cancer Institute (NCI) | 2002-08-01 |
| Imatinib Mesylate in Treating Patients With Myelofibrosis (NCT00039416) | National Cancer Institute (NCI) | 2002-04-01 |
| Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction (NCT00025415) | National Cancer Institute (NCI) | 2001-08-01 |
| Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer (NCT00112593) | Fred Hutchinson Cancer Center | 1999-11-01 |